Relapsing Multiple Sclerosis Pipeline Summary

DelveInsight’s, “Relapsing Multiple Sclerosis - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Relapsing Multiple Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Relapsing Multiple Sclerosis: Understanding

Relapsing Multiple Sclerosis: Overview

Relapsing multiple sclerosis (RMS) is a chronic, immune-mediated demyelinating disease of the central nervous system characterized by recurrent episodes of neurological dysfunction (relapses) followed by periods of partial or complete recovery (remission). The most common phenotype is relapsing-remitting multiple sclerosis (RRMS), which accounts for approximately 85% of initial MS diagnoses. The disease predominantly affects young adults, particularly women, and is thought to result from a combination of genetic susceptibility and environmental factors, including Epstein–Barr virus infection, vitamin D deficiency, smoking, and obesity.

Clinical manifestations vary depending on lesion location and commonly include optic neuritis, limb weakness, sensory disturbances, gait imbalance, diplopia, fatigue, cognitive impairment, bladder dysfunction, and spasticity. Although recovery often occurs after relapses, repeated inflammatory episodes may lead to cumulative neurological disability over time.

The pathophysiology of RMS involves immune-mediated inflammation directed against myelin and axons within the brain, spinal cord, and optic nerves. Activated autoreactive T cells, B cells, macrophages, and microglia cross the blood–brain barrier, triggering inflammatory demyelination, oligodendrocyte injury, axonal damage, and neurodegeneration. Acute inflammatory lesions produce clinical relapses, while incomplete remyelination and chronic neuroaxonal loss contribute to irreversible disability progression.

Diagnosis is based on the 2017 McDonald criteria, which require evidence of dissemination in space and time demonstrated by clinical findings and magnetic resonance imaging (MRI). Additional diagnostic investigations include cerebrospinal fluid analysis showing oligoclonal IgG bands, evoked potentials, and laboratory testing to exclude alternative inflammatory, infectious, or metabolic disorders.

Management of RMS aims to reduce relapse frequency, delay disability progression, and preserve neurological function through early initiation of disease-modifying therapy (DMT). Acute relapses are typically treated with high-dose intravenous or oral corticosteroids, while plasma exchange may be considered for severe steroid-refractory attacks. Long-term DMTs include injectable agents (interferon-?, glatiramer acetate), oral therapies (fingolimod, dimethyl fumarate, teriflunomide, ozanimod, ponesimod, cladribine), and high-efficacy monoclonal antibodies such as ocrelizumab, ofatumumab, natalizumab, alemtuzumab, and ublituximab, selected according to disease activity and patient characteristics. Comprehensive care also includes symptom management, rehabilitation, physical exercise, psychological support, smoking cessation, vitamin D optimization, and regular clinical and MRI monitoring to assess treatment response and disease progression.

"Relapsing Multiple Sclerosis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing Multiple Sclerosis pipeline landscape is provided which includes the disease overview and Relapsing Multiple Sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis Emerging Drugs Chapters

This segment of the Relapsing Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsing Multiple Sclerosis Emerging Drugs

IMU-838: Immunic AG

IMU-838 (vidofludimus calcium) is an investigational oral, selective dihydroorotate dehydrogenase (DHODH) inhibitor being developed as a disease-modifying therapy for relapsing multiple sclerosis (RMS). It is designed to selectively modulate activated immune cells, particularly autoreactive T and B lymphocytes, while aiming to preserve broader immune function. By reducing inflammatory immune activity, IMU-838 aims to decrease MS relapses, MRI lesion activity, and potential disease progression. The therapy is being evaluated in the randomized, double-blind Phase III trial assessing its efficacy, safety, and tolerability compared with placebo in adults with relapsing multiple sclerosis.

YTB323: Novartis

YTB323 (rapcabtagene autoleucel) is an investigational autologous CD19-directed CAR-T cell therapy being developed for relapsing multiple sclerosis (RMS) in patients with breakthrough disease activity despite prior highly efficacious therapies. It is designed as a single intravenous infusion to achieve deep and sustained depletion of CD19-positive B cells, with the goal of resetting the aberrant immune response that drives disease activity. By targeting pathogenic B cells, YTB323 aims to provide durable disease control and potentially reduce the need for continuous immunotherapy. The therapy is currently being evaluated in an open-label, multicenter Phase I/II clinical trial assessing its safety, efficacy, and cellular kinetics in adults with relapsing multiple sclerosis.

AZD0120: AstraZeneca

AZD0120 is an investigational autologous CD19/BCMA dual-targeting chimeric antigen receptor (CAR) T-cell therapy being developed for patients with refractory relapsing multiple sclerosis (RMS). The therapy is designed to target and eliminate pathogenic B-cell populations, including CD19- and BCMA-expressing cells, with the aim of resetting the dysregulated immune system underlying MS. AZD0120 is being evaluated as a potential one-time cellular therapy approach to achieve durable disease control and reduce inflammatory disease activity. The program is currently being studied in a Phase Ib, open-label, multicenter clinical trial assessing safety, tolerability, pharmacokinetics, B-cell depletion, and preliminary efficacy measures in adults with relapsing or progressive MS.

Further product details are provided in the report……..

Relapsing Multiple Sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Relapsing Multiple Sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Relapsing Multiple Sclerosis
• There are approx. 20+ key companies which are developing the therapies for Relapsing Multiple Sclerosis. The companies which have their Relapsing Multiple Sclerosis drug candidates in the most advanced stage, i.e. Phase III include, Immunic AG.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Relapsing Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsing Multiple Sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Relapsing Multiple Sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing Multiple Sclerosis drugs.

Relapsing Multiple Sclerosis Report Insights

• Relapsing Multiple Sclerosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsing Multiple Sclerosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Relapsing Multiple Sclerosis drugs?
• How many Relapsing Multiple Sclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing Multiple Sclerosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing Multiple Sclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsing Multiple Sclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Immunic AG
• Novartis
• AstraZeneca
• Roche
• ModernaTX, Inc.
• Bristol-Myers Squibb
• Sanofi
• Gilead Sciences
• Zenas BioPharma
• Cellerys

Key Products

• IMU-838
• YTB323
• AZD0120
• Fenebrutinib
• mRNA-1195
• BMS-986353
• Frexalimab
• KITE-363
• Obexelimab
• CLS12311